Ling Xu

机构：Xinyang Central Hospital · ORCID：0000-0001-9355-6136

发表论文 170 篇 · 总被引 4449 次 · h-index 41

代表论文

• Discovery and Optimization of a STING Agonist Platform for Application in Antibody Drug Conjugates (2023 · Journal of Medicinal Chemistry · 被引 55)
• SPI1 activates TGF ‐β1/ PI3K /Akt signaling through transcriptional upregulation of FKBP12 to support the mesenchymal phenotype of glioma stem cells (2023 · Brain Pathology · 被引 19)
• Efficacy and safety of durvalumab + chemotherapy vs. atezolizumab + chemotherapy in the treatment of small-cell lung cancer: a retrospective comparative cohort study (2023 · Journal of Thoracic Disease · 被引 18)
• Association of 10 Genetic Variations and 10 Environmental Factors with Myopia of Different Severities in Different Age Groups of People in Northeast China (2024 · Frontiers in Bioscience-Landmark · 被引 8)
• Complete chloroplast genome sequence of Syzygium samarangense (Myrtaceae) and phylogenetic analysis (2022 · Mitochondrial DNA Part B · 被引 6)
• 144 | UPDATED EFFICACY/SAFETY OF THE BRUTON TYROSINE KINASE (BTK) DEGRADER BGB‐16673 IN RELAPSED/REFRACTORY (R/R) CLL/SLL: RESULTS FROM THE ONGOING PHASE 1 CaDAnCe‐101 STUDY (2025 · Hematological Oncology · 被引 5)